Verition Fund Management’s Aclaris Therapeutics ACRS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-35,805
| Closed | -$54.8K | – | 2867 |
|
|
2025
Q1 | $54.8K | Buy |
+35,805
| New | +$54.8K | ﹤0.01% | 2524 |
|
|
2024
Q3 | – | Sell |
-82,883
| Closed | -$91.2K | – | 2441 |
|
|
2024
Q2 | $91.2K | Buy |
82,883
+29,048
| +54% | +$32K | ﹤0.01% | 2086 |
|
|
2024
Q1 | $66.8K | Buy |
+53,835
| New | +$66.8K | ﹤0.01% | 2011 |
|
|
2023
Q4 | – | Sell |
-299,685
| Closed | -$2.05M | – | 1845 |
|
|
2023
Q3 | $2.05M | Sell |
299,685
-351,242
| -54% | -$2.41M | 0.02% | 689 |
|
|
2023
Q2 | $6.75M | Buy |
650,927
+37,475
| +6% | +$389K | 0.09% | 263 |
|
|
2023
Q1 | $4.96M | Buy |
613,452
+207,884
| +51% | +$1.68M | 0.07% | 333 |
|
|
2022
Q4 | $6.39M | Buy |
405,568
+33,061
| +9% | +$521K | 0.1% | 215 |
|
|
2022
Q3 | $5.86M | Buy |
372,507
+37,841
| +11% | +$596K | 0.07% | 318 |
|
|
2022
Q2 | $4.67M | Buy |
334,666
+79,188
| +31% | +$1.11M | 0.09% | 271 |
|
|
2022
Q1 | $4.4M | Buy |
255,478
+77,168
| +43% | +$1.33M | 0.05% | 322 |
|
|
2021
Q4 | $2.59M | Buy |
+178,310
| New | +$2.59M | 0.02% | 482 |
|
|
2021
Q1 | – | Sell |
-98,845
| Closed | -$640K | – | 1405 |
|
|
2020
Q4 | $640K | Buy |
+98,845
| New | +$640K | 0.01% | 499 |
|
|
2020
Q3 | – | Sell |
-65,000
| Closed | -$105K | – | 944 |
|
|
2020
Q2 | $105K | Buy |
+65,000
| New | +$105K | ﹤0.01% | 923 |
|